New trials, publications, preprints and grants on this target, month by month.
Trial
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
1 Mar 2028· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Multi-CAR-T Cells Targeting B Cell Lymphomas
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer
26 Feb 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
1 Feb 2027· PHASE4 · NOT_YET_RECRUITING· CTGOV
Trial
New diagnostic pathway in primary diagnosis of clinically significant prostate cancer adding PSMA-PET to mpMRI
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTIS
Trial
PSMA-specific CAR-T Cell Therapy
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
GD2/PSMA Bi-specific CAR-T Cell Therapy
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer
30 Dec 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
Safety and Efficacy of OTL78
1 Dec 2026· PHASE2_PHASE3 · RECRUITING· CTGOV
Trial
POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions
1 Dec 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer
1 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
15 Nov 2026· PHASE2 · RECRUITING· CTGOV
Publication
Patient Communication and Radiation Safety in [177Lu]Lu-PSMA Radiopharmaceutical Therapy: International Survey of 102 Theranostic Centers.
5 Nov 2026· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publication
Preclinical Physiologically Based Pharmacokinetic Modeling of PSMA Radioligands: Demonstrating Nonspecific Retention and Reversible Albumin-Binding Effects.
5 Nov 2026· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publication
PSMA PET Before Prostate Biopsy: From Lesion Detection to Biopsy Avoidance.
4 Nov 2026· The French journal of urology· PUBMED
Publication
Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer.
3 Nov 2026· Molecular cancer therapeutics· PUBMED
Publication
Dural Metastases from Prostate Cancer Mimicking Meningioma on PSMA PET/CT.
3 Nov 2026· Revista espanola de medicina nuclear e imagen molecular· PUBMED
Trial
Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer
2 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Fully Automated Segmentation of [18F]FDG and [68Ga]/[18F]PSMA PET/CT Images via Data-Centric Deep Learning.
2 Nov 2026· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publication
Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [177Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.
2 Nov 2026· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publication
The Global Theranostics Access Gap: Real-World Disparities in PSMA PET/CT and 177Lu-PSMA Therapy Between Centers in Brazil and Europe.
2 Nov 2026· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publication
The PRIMARY Scoring System on PSMA PET for Clinically Significant Prostate Cancer Detection: A Systematic Review and Meta-Analysis: Erratum.
2 Nov 2026· Clinical nuclear medicine· PUBMED
Publication
Prognostic Value of [18F]FDG PET Combined with [68Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617.
2 Nov 2026· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publication
PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study.
2 Nov 2026· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Trial
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
1 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTIS
Trial
Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma
1 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV